Shimizu Hiroyuki
Department of Virology II, National Institute of Infectious Diseases.
Nihon Rinsho. 2011 Sep;69(9):1604-8.
During the final stage of global polio eradication program, universal use of inactivated poliovirus vaccine (IPV) is the most feasible option to minimize the inherent risk of oral poliovirus vaccine (OPV), such as vaccine-associated paralytic poliomyelitis (VAPP) and polio outbreaks due to vaccine-derived polioviruses. Introduction of diphtheria, pertussis, tetanus, IPV (DPT-IPV) products, instead of OPV, to routine polio immunization should be seriously and urgently considered to minimize ongoing risk of VAPP in Japan. Accordingly, a further polio immunization strategy, including the immunization schedule using DPT-IPV, interchangeability of different DPT-IPV products, intensified polio surveillance activities, and appropriate polio vaccine stockpile, should be developed to maintain polio-free status in Japan prior to the introduction of DPT-IPV.
在全球根除脊髓灰质炎计划的最后阶段，普遍使用灭活脊髓灰质炎病毒疫苗（IPV）是将口服脊髓灰质炎病毒疫苗（OPV）的固有风险降至最低的最可行选择，这些风险包括疫苗相关麻痹性脊髓灰质炎（VAPP）以及疫苗衍生脊髓灰质炎病毒导致的脊髓灰质炎疫情。应认真且紧急地考虑在日本常规脊髓灰质炎免疫中引入白喉、百日咳、破伤风、IPV（DPT-IPV）产品，而非OPV，以将日本持续存在的VAPP风险降至最低。因此，应制定进一步的脊髓灰质炎免疫策略，包括使用DPT-IPV的免疫程序、不同DPT-IPV产品的互换性、强化脊髓灰质炎监测活动以及适当的脊髓灰质炎疫苗储备，以便在引入DPT-IPV之前维持日本无脊髓灰质炎状态。
